Literature DB >> 31148335

Is low-level HIV-1 viraemia associated with elevated levels of markers of immune activation, coagulation and cardiovascular disease?

O Elvstam1, P Medstrand1, M Jansson2, P E Isberg3, M Gisslén4,5, P Björkman1.   

Abstract

OBJECTIVES: The clinical significance of low-level viraemia (LLV) during antiretroviral therapy (ART) is debated. We retrospectively investigated longitudinal levels of plasma markers associated with inflammation, altered coagulation and cardiovascular disease in Swedish HIV-positive adults in relation to LLV or permanent virological suppression during long-term ART.
METHODS: Plasma levels of C-reactive protein (CRP), D-dimer, vascular cell adhesion molecule 1 (VCAM-1), suppression of tumorigenicity 2 (ST2), growth differentiation factor 15 (GDF-15), soluble CD14 (sCD14), soluble CD163 (sCD163), interferon-γ-induced protein 10 (IP-10) and β-2-microglobulin were measured in 34 individuals with LLV (viral load 50-999 HIV-1 RNA copies/mL) and in matched controls with persistent virological suppression. Biomarker levels were analysed in samples obtained during episodes of LLV and follow-up samples obtained 1 year later (with similar timing for controls). All biomarkers were analysed using an independent sample t-test and analysis of covariance (ANCOVA) after logarithmic transformation. Log-rank analysis was applied for markers with concentration values out of range.
RESULTS: Compared with controls, patients with LLV had significantly higher levels of GDF-15 [geometric mean 3416 (95% confidence interval (CI) 804-14 516) pg/mL versus 2002 (95% CI 355-11 295) pg/mL in controls; P = 0.026] and D-dimer [mean 1114 (95% CI 125-9917) ng/mL versus 756 (95% CI 157-3626) ng/mL; P = 0.038] after adjustment for age, CD4 count nadir and type of ART. In the unadjusted t-test, only GDF-15 was significantly higher and in the log-rank test, both GDF-15 and D-dimer were significantly elevated. No significant differences were observed for the other biomarkers analysed.
CONCLUSIONS: Although levels of inflammation markers were similar in ART recipients with and without LLV, persons with LLV had significantly higher levels of GDF-15 and D-dimer. These findings suggest a potential link between LLV and cardiovascular outcomes.
© 2019 British HIV Association.

Entities:  

Keywords:  zzm321990HIVzzm321990; cardiovascular disease; coagulation; inflammation; low-level viraemia

Mesh:

Substances:

Year:  2019        PMID: 31148335     DOI: 10.1111/hiv.12756

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  7 in total

1.  Association of intestinal and systemic inflammatory biomarkers with immune reconstitution in HIV+ patients on ART.

Authors:  Mariana Del Rocio Ruiz-Briseño; Judith Carolina De Arcos-Jiménez; Sarah Ratkovich-González; Karina Sánchez-Reyes; Luz A González-Hernández; Jaime F Andrade-Villanueva; Monserrat Alvarez-Zavala
Journal:  J Inflamm (Lond)       Date:  2020-10-15       Impact factor: 4.981

2.  Cardiovascular Profile of South African Adults with Low-Level Viremia during Antiretroviral Therapy.

Authors:  Shani Botha-Le Roux; Olof Elvstam; Patrick De Boever; Nandu Goswami; Martin Magnusson; Peter M Nilsson; Hans Strijdom; Per Björkman; Carla M T Fourie
Journal:  J Clin Med       Date:  2022-05-16       Impact factor: 4.964

3.  All-Cause Mortality and Serious Non-AIDS Events in Adults With Low-level Human Immunodeficiency Virus Viremia During Combination Antiretroviral Therapy: Results From a Swedish Nationwide Observational Study.

Authors:  Olof Elvstam; Gaetano Marrone; Patrik Medstrand; Carl Johan Treutiger; Anders Sönnerborg; Magnus Gisslén; Per Björkman
Journal:  Clin Infect Dis       Date:  2021-06-15       Impact factor: 9.079

4.  Heightened levels of plasma growth differentiation factor 15 in men living with HIV.

Authors:  Neeti Agarwal; Claudia E Ramirez Bustamante; Huaizhu Wu; Reina Armamento-Villareal; Jordan E Lake; Ashok Balasubramanyam; Sean M Hartig
Journal:  Physiol Rep       Date:  2022-05

5.  Associations of FGF21 and GDF15 with mitochondrial dysfunction in children living with perinatally-acquired HIV: A cross-sectional evaluation of pediatric AIDS clinical trials group 219/219C.

Authors:  Greg S Gojanovich; Denise L Jacobson; Carly Broadwell; Brad Karalius; Brian Kirmse; Mitchell E Geffner; Jennifer Jao; Russell B Van Dyke; Elizabeth J McFarland; Margarita Silio; Marilyn Crain; Mariana Gerschenson
Journal:  PLoS One       Date:  2021-12-31       Impact factor: 3.240

Review 6.  Two-Drug Regimens for HIV-Current Evidence, Research Gaps and Future Challenges.

Authors:  Alexandre Pérez-González; Inés Suárez-García; Antonio Ocampo; Eva Poveda
Journal:  Microorganisms       Date:  2022-02-14

Review 7.  Persistent low-Level viremia in persons living with HIV undertreatment: An unresolved status.

Authors:  Celia Crespo-Bermejo; Eva Ramírez de Arellano; Violeta Lara-Aguilar; Daniel Valle-Millares; Mª Luisa Gómez-Lus; Ricardo Madrid; Luz Martín-Carbonero; Verónica Briz
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.